TransMedics Group, Inc. (TMDX) saw its stock surge 5.22% in the intraday session on Tuesday, following the company's impressive fourth-quarter 2024 financial results and optimistic guidance for the current year.
The medical technology company reported strong revenue growth for Q4 2024, with revenue reaching $122 million, representing a significant increase from the previous year. Additionally, TransMedics recorded a notable jump in net income, climbing to nearly $7 million, a remarkable turnaround from the net loss reported in the prior year.
Investors were further buoyed by TransMedics' positive revenue guidance for 2025, with the company anticipating a 20% to 25% increase in revenue. This outlook likely fueled confidence in the company's growth prospects, driving the stock's substantial intraday gain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.